All In Biotech

Drug Trial Radar · NCT05564169

Masitinib in Patients With Mild Alzheimer's Disease

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib as add-on Therapy in Patients With Mild Alzheimer's Disease, Treated With Standard of Care

Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
AB ScienceIndustry
Sponsor type
Industry
First posted
Oct 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

  • PlaceboDrug

    treatment per os

  • Masitinib (4.5)Drug

    Masitinib (titration to 4.5 mg/kg/day)

  • Standard of careDrug

    Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change from baseline in iADRS score at week 24Time frame: 24 weeks

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Institut de la mémoire et Maladie d'Alzheimer, Hôpitaux Universitaires Pitié-Salpêtrière

    Paris, France

  • Hospital Universitario Nuestra Señora del Perpetuo Socorro de Albacete (Hospital Universitario Nuestra Señora del Perpétuo Socorro)

    Albacete, Spain

  • Ace Alzheimer Center Barcelona (Fundació ACE)

    Barcelona, Spain

  • Hospital Policlínico de Gipuzkoa

    Donostia / San Sebastian, Spain

  • Virgen de las Nieves University Hospital (Hospital Universitario Virgen de las Nieves)

    Granada, Spain

  • La Paz University Hospital (Hospital Universitario La Paz)

    Madrid, Spain

  • Hospital Clinico Universitario Virgen de la Arrixaca

    Murcia, Spain

  • Hospital Universitario de Navarra

    Pamplona, Spain

  • Complejo Asistencial de Zamora. Hospital Provincial de Zamora

    Zamora, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.